JAMA Dermatology

A cross-sectional analysis of commercial insurance claims from 2431 US #hospitals assessed negotiated prices for 15 common dermatologic procedures. Substantial variability was observed: median commercial payer-negotiated prices were typically lower than hospital list prices and higher than Medicare rates, with between-hospital variation exceeding within-hospital variation in every case. These findings highlight wide geographic and payer-related disparities in #Dermatology procedure costs, underscoring the need for ongoing price transparency and monitoring to support equitable #patient care. https://ja.ma/3SipbSn

📄 This case report describes 2 household members who presented with intensely pruritic eruptions from the scalp to the extremities. https://ja.ma/4eCkCtv

A randomized clinical trial evaluated daily emollient use beginning before age 9 weeks for the prevention of #AtopicDermatitis in US infants not selected for risk. Assignment to daily moisturizer reduced eczema incidence by 16% at age 2 years, with safety demonstrated across a large, diverse cohort. These findings differ from prior smaller trials in high-risk groups, emphasizing the feasibility of population-based #skincare prevention in #pediatric primary care. JAMA Dermatology Editor in Chief Kanade Shinkai, MD, PhD, named this trial Editor’s Choice for Clinical Trial of 2025 for its methodological rigor, inclusion of underrepresented populations, and ability to inform #clinical and #policy approaches to pediatric #Eczema. The study highlights the importance of large, community-based randomized controlled trials in guiding evidence-based practice. 📌 How can clinicians and researchers stay up to date on the most clinically relevant trials? JAMA+ Trials highlights the implications and innovations of clinical trial research from across the JAMA Network to advance evidence-based medicine and public health. Follow JAMA+ Trials to get curated access to the best of the JAMA Network’s trial research, commentaries, and educational resources. 📬 Sign up for the JAMA+ Trials email newsletter: https://ja.ma/4axnoik 📖 Read the full trial: https://ja.ma/4eUN3UI

In a large cohort of adults with hypopigmented #mycosis #fungoides, most had early-stage disease and responded well to skin-directed therapy, with stage progression observed in only 6%. https://ja.ma/4aHP83X

Facial #aging is a natural and progressive form of senescence that can have significant psychosocial impacts. Common features include rhytids, dyspigmentation, changes in facial fat, and skin textural changes. Treatments range from noninvasive to minimally invasive and fully invasive procedures. This consensus statement develops a core outcome set of essential domains to be reported in clinical trials evaluating the efficacy of interventions for facial aging. https://ja.ma/43GkG6y

In refractory #rosacea, paroxetine therapy was associated with systemic proteomic changes in neuro-vascular-immune pathways and identified circulating protein #biomarkers linked to #clinical improvement. https://ja.ma/4vQ3Aio

A multicenter retrospective cohort study examined the clinicopathologic features and long-term outcomes of adult hypopigmented mycosis fungoides (HMF), a rare cutaneous T-cell lymphoma variant. Among 224 adults (median age, 44 years; 83% Black; 73% women), most (98%) presented with early-stage disease. The majority (71%) had hypopigmented lesions only, while 29% exhibited mixed hypopigmented and nonhypopigmented lesions. Over a median 39-month follow-up, 90% of treated patients received skin-directed therapy, with an overall response rate of 77%. Stage progression was uncommon (6%), and peripheral blood T-cell receptor monoclonality, present in 27% of those tested, was associated with reduced treatment response but not with progression. These findings indicate that adult HMF typically follows an indolent course responsive to skin-directed therapies, irrespective of immunophenotype or lesion variant. https://ja.ma/4vbrHs5

In a secondary proteomic analysis of a randomized clinical trial, patients with refractory erythematous #Rosacea received 12 weeks of oral paroxetine therapy to explore systemic molecular changes associated with clinical response. Paired plasma samples revealed 497 differentially expressed proteins after treatment; downregulated proteins were enriched in immune response, insulin signaling, and neuronal remodeling pathways. A subset of 98 reversed-response proteins was associated with synaptic vesicle cycles and vascular smooth muscle contraction. Changes in protein expression correlated with improvements in erythema and flushing severity, and exploratory receiver operating characteristic analysis identified candidate biomarkers—such as OLFML3 and IGFBP2—that showed high predictive value for clinical improvement. These findings suggest that paroxetine modulates systemic neuro-vascular-immune networks in rosacea and identifies circulating protein signatures that may facilitate future personalized approaches. https://ja.ma/4uzpSE5

An economic evaluation assessed the cost-effectiveness of oral nicotinamide for keratinocyte carcinoma prevention within the Veterans Health Administration. Among over 33 000 individuals with keratinocyte carcinoma history, nicotinamide use reduced annual cancer incidence, preventing an estimated 624 cancers per year and resulting in net cost savings of $364 581. The intervention produced additional quality-adjusted life-years (QALYs) and consistently met cost-effectiveness thresholds across sensitivity and scenario analyses. These findings support oral nicotinamide as a cost-effective, patient-centered option for secondary prevention of keratinocyte carcinoma in high-risk populations. https://ja.ma/4vAEy6N

A population-based, ecological comparative effectiveness study assessed whether the German #SkinCancer screening program, implemented in 2008 for adults ≥35 years, was associated with reduced melanoma mortality compared to nine neighboring countries without population-based screening. Between 2009 and 2022, age-standardized melanoma mortality rates declined in Germany and control regions, but the annual percentage change in mortality was not statistically different (Germany: -1.8% per year, control regions: -2.2% per year). These findings indicate that the German screening program did not provide a detectable melanoma mortality benefit vs standard care in neighboring countries. Future evaluation of the program should address underlying reasons for its limited impact, including low participation rates, screening quality, and possible ecological study design limitations. https://ja.ma/4e27aQJ